---
title: "Understanding the Market | TRANSTHERA-B once surged over 25% after announcing research data on Tengrutini at the 2025 ESMO Annual Meeting and receiving an oral presentation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262145517.md"
description: "TRANSTHERA-B's stock price once rose more than 25%, and as of the time of publication, the increase was 15.81%, reported at HKD 200, with a transaction volume of HKD 712 million. The company announced that it will present the latest research data on tepotinib for the indication of cholangiocarcinoma at the 2025 European Society for Medical Oncology (ESMO) annual meeting. Tepotinib is an innovative multi-target small molecule kinase inhibitor that has conducted multiple clinical trials in China and the United States and has received several drug certifications"
datetime: "2025-10-22T01:57:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262145517.md)
  - [en](https://longbridge.com/en/news/262145517.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262145517.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/262145517.md) | [繁體中文](https://longbridge.com/zh-HK/news/262145517.md)


# Understanding the Market | TRANSTHERA-B once surged over 25% after announcing research data on Tengrutini at the 2025 ESMO Annual Meeting and receiving an oral presentation

According to Zhitong Finance APP, TRANSTHERA-B (02617) once rose over 25%, and as of the time of writing, it is up 15.81%, priced at HKD 200, with a trading volume of HKD 712 million.

In terms of news, according to TRANSTHERA's official WeChat account, on October 20th, TRANSTHERA announced that the company presented the latest summary research data of its core product, Tienogatinib, for the indication of cholangiocarcinoma at the 2025 European Society for Medical Oncology (ESMO) annual meeting.

It is reported that Tienogatinib is an innovative multi-target small molecule kinase inhibitor developed independently and is in the registration clinical phase. It exerts anti-tumor effects by targeting tumor cells and improving the tumor microenvironment. Currently, Tienogatinib has conducted multiple clinical trials targeting solid tumors such as cholangiocarcinoma, prostate cancer, and breast cancer in both China and the United States, and has received the "Orphan Drug Designation" (ODD) for the treatment of cholangiocarcinoma from the U.S. FDA, "Fast Track Designation," as well as "Fast Track Designation" for the treatment of prostate cancer. The China NMPA has approved its inclusion in the list of breakthrough therapy varieties, and the European EMA has granted orphan drug designation (ODD) for the treatment of biliary tract cancer

### Related Stocks

- [TRANSTHERA-B (02617.HK)](https://longbridge.com/en/quote/02617.HK.md)

## Related News & Research

- [Bye Bye, NVDA! Cathie Wood Dumps Nearly $30 Million in Nvidia](https://longbridge.com/en/news/281559711.md)
- [SK Hynix appoints underwriters for its US listing, South Korean newspaper says](https://longbridge.com/en/news/281594027.md)
- [Nvidia (NVDA) H100 Prices Surge 40% as New GPUs Fail to Meet Insatiable Demand](https://longbridge.com/en/news/281588202.md)
- [Tesla Posts One Of Its Worst Sales Quarters In Years—Prediction Markets Saw It Coming](https://longbridge.com/en/news/281548812.md)
- [Tesla Expands EV and Energy Reach in Q1](https://longbridge.com/en/news/281560227.md)